Context Therapeutics (CNTX) Equity Ratio (2020 - 2026)

Context Therapeutics has disclosed Equity Ratio across 7 years of filings, most recently posting 0.89 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.89, down 9.38% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.89 (down 9.38% YoY), and the FY2025 annual result was 0.88, down 9.06% from the prior year.
• Equity Ratio came in at 0.89 for Q1 2026 at Context Therapeutics, roughly flat from 0.88 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.98 in Q2 2024 to a low of 0.74 in Q4 2023.
• The 5-year median for Equity Ratio is 0.92 (2022), against an average of 0.9.
• Across the five-year window, Equity Ratio soared 108.8% in 2022 and dropped 19.28% in 2023, its largest moves.
• Context Therapeutics' Equity Ratio stood at 0.92 in 2022, then decreased by 19.28% to 0.74 in 2023, then surged by 31.37% to 0.97 in 2024, then decreased by 9.06% to 0.88 in 2025, then climbed by 0.45% to 0.89 in 2026.
• The last three Equity Ratio figures came in at 0.89 (Q1 2026), 0.88 (Q4 2025), and 0.92 (Q3 2025), per Business Quant data.